Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Jun 2007

Sanchez-Carbayo Marta, Socci Nicholas D, Kirchoff Thomas, Erill Nadina, Offit Keneth, Bochner Bernard H, Cordon-Cardo Carlos

Abstract excerpt

PURPOSE: The HDM2 gene represents one of the central nodes in the p53 pathway. A recent study reported the association of a single nucleotide polymorphism (SNP309) in the HDM2 promoter region with accelerated tumor formation in both hereditary and sporadic cancers. In this study, we aim to evalua...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene Expression Profiling
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, p53

Share to Homozygote

Share to Oligonucleotide Array Sequence Analysis

Share to Proto-Oncogene Proteins c-mdm2

Share to Treatment Outcome

Share to Urinary Bladder Neoplasms

Source

Identifiers

PMID: 17545525
DOI: 10.1158/1078-0432.CCR-07-0013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17545525-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.PMID 17545525Read ↗

Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.Semantic proximity Read ↗

The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.Semantic proximity Read ↗

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.Semantic proximity Read ↗

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Semantic proximity Read ↗

MDM2 SNP309 associates with accelerated pancreatic adenocarcinoma formation.Semantic proximity Read ↗

MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism.Semantic proximity Read ↗

MDM2 promoter polymorphism SNP309 contributes to tumor susceptibility: evidence from 21 case-control studies.Semantic proximity Read ↗

The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis.Semantic proximity Read ↗

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.Semantic proximity Read ↗

MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.Semantic proximity Read ↗

Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status.Semantic proximity Read ↗

MDM2 T309G polymorphism is associated with bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.